Vitamin B12 deficiency affects an estimated 6% of adults under 60 and up to 20% of those over 60 in the United States, yet deficiency often goes undetected for years because hepatic stores are substantial — the liver holds approximately 1–5 mg, enough to last 3–5 years even with complete dietary cessation (Allen, 2009). By the time deficiency becomes clinically apparent through blood tests, neurological damage may already be underway. Understanding B12's unique biochemistry, absorption requirements, and high-risk populations is essential for anyone aiming to maintain energy, cognitive clarity, and long-term nerve health.
This guide covers the full picture: what B12 does at the cellular level, why absorption fails in common conditions, and how to restore and maintain optimal levels. Related: Vitamin C and Collagen: Skin Health Guide
What Vitamin B12 Does
Vitamin B12 (cobalamin) is the largest and structurally most complex water-soluble vitamin, with a cobalt ion at its centre coordinated by a corrin ring. It functions as a cofactor for two essential enzyme reactions in humans:
1. Methylmalonyl-CoA Mutase
This mitochondrial enzyme converts methylmalonyl-CoA to succinyl-CoA, feeding odd-chain fatty acids and some amino acids (threonine, methionine, valine, isoleucine) into the citric acid cycle. Without adequate B12, methylmalonyl-CoA accumulates, producing methylmalonic acid (MMA) in blood and urine — an early and sensitive biomarker of B12 insufficiency. Abnormal fatty acid incorporation into myelin sheaths may be the primary mechanism of B12-related neurological damage.
2. Methionine Synthase
This cytoplasmic enzyme converts homocysteine to methionine using methylcobalamin (the active form) and 5-methyltetrahydrofolate as methyl donor. This is a pivotal reaction in the methyl cycle: methionine is converted to S-adenosylmethionine (SAM), the universal methyl donor for DNA methylation, neurotransmitter synthesis, phospholipid methylation, and gene expression regulation. B12 deficiency therefore impairs SAM regeneration, causing hyperhomocysteinaemia and broad downstream methylation failures.
How B12 Is Absorbed
B12 absorption is uniquely complex compared to other water-soluble vitamins, explaining why deficiency can occur even with adequate dietary intake when the absorptive machinery is compromised.
- Gastric acid release: Dietary B12 is bound to food proteins. Gastric acid (HCl) and pepsin cleave it free in the stomach. Proton pump inhibitor (PPI) drugs or atrophic gastritis reduce HCl secretion, impairing this first step.
- Haptocorrin binding: Freed B12 binds to haptocorrin (R-binder proteins) secreted by salivary glands and gastric mucosa, protecting it from acid degradation.
- Intrinsic factor production: Gastric parietal cells secrete intrinsic factor (IF). In the duodenum, pancreatic proteases degrade haptocorrin; B12 then binds IF to form the B12-IF complex.
- Ileal absorption: The B12-IF complex binds to cubilin receptors in the terminal ileum and is internalised by receptor-mediated endocytosis. This pathway has a maximum absorption rate of approximately 1.5–2 mcg per dose. For doses above this, a secondary non-IF-dependent passive absorption pathway (~1% of dose) becomes proportionally more important.
Who Is at Risk of Deficiency?
| Risk Factor | Mechanism | Estimated Prevalence of Deficiency |
|---|---|---|
| Strict vegans / vegetarians | No dietary B12 (B12 only in animal-derived foods) | 52–70% in vegans without supplementation |
| Adults over 60 | Reduced gastric acid, atrophic gastritis | 15–20% |
| Pernicious anaemia | Autoimmune destruction of parietal cells → no intrinsic factor | ~1% of population; 50% of severe deficiency cases |
| Long-term PPI or H2-blocker use | Reduced gastric acid, impaired food-bound B12 release | 4–10% increased risk with >2 years use |
| Metformin use | Reduces calcium-dependent B12-IF absorption in ileum | 10–30% reduction in B12 levels |
| Ileal resection or Crohn's disease | Loss of cubilin receptor site | High without supplementation |
| Pregnancy | Increased demand; fetal B12 dependent on maternal status | Supplementation universally recommended |
Symptoms and Neurological Effects
B12 deficiency presents across haematological and neurological systems, often simultaneously but sometimes in isolation. Understanding both presentations is important because the neurological manifestations can occur even without anaemia.
Haematological
B12 deficiency impairs DNA synthesis in rapidly dividing cells. Megaloblastic anaemia occurs when red blood cell precursors cannot divide normally, producing oversized, non-functional macrocytes. Symptoms: fatigue, pallor, shortness of breath on exertion, elevated MCV on blood count. Serum B12 below 200 pg/mL combined with elevated MCV is a classic presentation.
Neurological — Subacute Combined Degeneration
The most serious consequence of prolonged B12 deficiency is subacute combined degeneration of the spinal cord — demyelination of the posterior and lateral columns of the spinal cord. Early symptoms include: symmetrical paraesthesiae (tingling, numbness) in hands and feet; loss of proprioception and vibration sense; progressive weakness; and balance disturbance. Without treatment, this progresses to permanent motor and sensory deficits. Critically, neurological damage can precede haematological changes in up to 25% of cases, especially in patients whose folate intake is adequate (Stabler, 2013).
Cognitive and Neuropsychiatric
Hyperhomocysteinaemia secondary to B12 deficiency is associated with accelerated brain atrophy, elevated dementia risk, and neuropsychiatric symptoms including depression, cognitive slowing, and in severe cases, psychosis. A meta-analysis by Smith et al. found that elevated homocysteine was associated with a twofold increased risk of Alzheimer's disease.
Food Sources and Bioavailability
B12 is synthesised exclusively by microorganisms and is found only in animal-derived foods or fortified products. Bioavailability from food varies by matrix:
- Clams and oysters: Highest concentration per gram (84 mcg per 100 g for clams). Also rich in zinc and iron.
- Liver (beef): 70 mcg per 100 g; bioavailability approximately 65–70%.
- Salmon and trout: 3–4 mcg per 100 g; excellent overall B12 source given typical serving sizes.
- Eggs: 1.1 mcg per 100 g; however, nearly all is bound to the yolk and as egg-white avidin may impair biotin absorption from raw eggs. Bioavailability ~9% compared to crystalline supplements.
- Dairy (milk, cheese, yogurt): 0.4–1.2 mcg per 100 g; notably, B12 from milk is significantly more bioavailable than from meat due to the absence of tight protein binding.
- Fortified plant milks and cereals: Contain crystalline cyanocobalamin with high bioavailability (50–60% at physiological doses); the primary reliable source for vegans.
Supplementation: Forms and Dosing
Three supplemental forms are available: cyanocobalamin, methylcobalamin, and hydroxocobalamin. All are effective at reversing deficiency; selection depends on context:
- Cyanocobalamin: Most stable, cheapest, and most extensively studied form. Converted to methylcobalamin and adenosylcobalamin in vivo. Contains a small cyanide molecule that is cleared by hepatic rhodanese — negligible amounts at standard doses but a consideration in heavy smokers or renal impairment.
- Methylcobalamin: The active cofactor form for methionine synthase; crosses the blood-brain barrier more readily. Preferred by practitioners for neurological indications. Less stable than cyanocobalamin and should be protected from light.
- Hydroxocobalamin: Administered as intramuscular injection for severe deficiency or pernicious anaemia; retained longer than cyanocobalamin after injection.
Oral dosing strategy depends on absorption pathway:
- For normal absorption: 10–25 mcg/day as part of a B-complex, or 2.4 mcg/day from fortified foods or diet (the RDA).
- For malabsorption (PPI use, atrophic gastritis): 500–1000 mcg/day — at this dose, passive non-IF absorption (~1%) provides approximately 5–10 mcg, more than meeting requirements.
- For pernicious anaemia: Traditional treatment is monthly intramuscular injections of 1000 mcg hydroxocobalamin; however, high-dose oral supplementation (1000–2000 mcg/day) has been shown to be equivalent in most patients (Vidal-Alaball et al., 2005 Cochrane review).
B12 Nutrition and Light Wellness
At a cellular level, B12's role in methionine synthase connects it to methylation of the mitochondrial genome and maintenance of mitochondrial protein synthesis. Mitochondria maintain their own circular DNA (mtDNA), and SAM-dependent methylation of mtDNA promoters regulates mitochondrial gene expression. B12 deficiency therefore has secondary effects on mitochondrial function beyond the direct enzymatic roles — impaired myelin maintenance affects nerve conduction velocity, while impaired SAM regeneration can disrupt neurotransmitter synthesis and cellular repair processes.
Near-infrared light at 810–850 nm exerts its primary biological effects on cytochrome c oxidase in the mitochondrial inner membrane. The B12-mitochondria connection is relevant because both B12 adequacy and NIR light wellness tools target the same organelle via distinct mechanisms. There is no established synergistic protocol combining B12 and NIR in human trials; however, ensuring B12 adequacy is a foundational step before expecting full benefit from any mitochondria-targeted intervention.
